[ad_1]
NEW YORK, Feb. 3, 2019 (GLOBE NEWSWIRE) – Bragar Eagel & Squire, P.C. is investigating potential claims against AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO). Our investigation is to determine whether AVEO has violated federal securities laws and / or is engaged in other illegal business practices.
Click on right here participate in the action.
On January 31, 2019, the Boston Business Journal reported that "Aveo had revealed that it would not submit its application to the FDA for approval because of a recommendation from the company." agency, which was to gather more test results in the final phase. More specifically, the FDA is asking for additional data on survival, echoing the concerns that led to its rejection of the same drug in 2013.
On this news, AVEO's share price fell by more than 56%, closing at $ 0.76 on January 31, 2019.
If you have purchased or otherwise acquired AVEO shares and have suffered a loss, if you have any information, wish to know more about these claims, or if you have any questions regarding this announcement, your rights or interests in relation to these matters, please contact Brandon Walker or Melissa Fortunato. by email to [email protected], or call (212) 355-4648, or by fill in this contact form. There is no cost or obligation for you.
Bragar Eagel & Squire, P.C. is a New York-based law firm specializing in commercial litigation and securities litigation. For more information on our AVEO survey, please visit: http://www.bespc.com/aveo/. For more information on Bragar Eagel & Squire, P.C., go to the address www.bespc.com. Public Prosecutor. Previous results do not guarantee similar results.
contacts
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
[email protected]
www.bespc.com
Source link
